Company / R&D Expense
Day One Biopharmaceuticals, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$148.1M
FY2025
5-year range
$43.6M / $227.7M
FY2021-FY2025
Trend
-34.9%
vs FY2024
Sector context
#105 of 209
Health Care
What the data says
At $148M, Day One Biopharmaceuticals, Inc.'s r&d expense ranks #105 of 209 in the Health Care sector. Improved from $131M to $148M over the past 2 years.
Based on SEC 10-K filings.
$148M in FY2025 with a 5-year CAGR of +74.7%.
Improved from $131M to $148M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +20.1%
- 5-Year CAGR
- +74.7%
- 10-Year CAGR
- -
Sector benchmark
#105 of 209 in Health CareTop 50% of 209This company $148.1M Sector average $647.6M
▼
-77.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +74.7%, indicating consistent growth.
- In FY2025, r&d expense decreased 34.9% year-over-year.
- Ranks #105 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $148.1M | -34.9% |
| FY2024 | $227.7M | +74.5% |
| FY2023 | $130.5M | +52.4% |
| FY2022 | $85.6M | +96.4% |
| FY2021 | $43.6M | +378.9% |
| FY2020 | $9.1M | -34.5% |
| FY2019 | $13.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026